CRDF has 36-month beta value of 1.56. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRDF is 60.75M, and currently, short sellers hold a 29.03% ratio of that float. The average trading volume of CRDF on June 18, 2025 was 1.16M shares.
CRDF) stock’s latest price update
The stock of Cardiff Oncology Inc (NASDAQ: CRDF) has decreased by -14.44 when compared to last closing price of 3.70.Despite this, the company has seen a loss of -18.10% in its stock price over the last five trading days. marketwatch.com reported 2025-06-17 that Sidhu joined Cardiff from Treadwell Therapeutics, where he was medical chief and acting chief executive officer. Previously, Sidhu spent nearly 10 years at Amgen.
CRDF’s Market Performance
Cardiff Oncology Inc (CRDF) has seen a -18.10% fall in stock performance for the week, with a 8.78% gain in the past month and a -17.56% plunge in the past quarter. The volatility ratio for the week is 2.52%, and the volatility levels for the past 30 days are at 4.78% for CRDF.. The simple moving average for the past 20 days is -9.79% for CRDF’s stock, with a -3.57% simple moving average for the past 200 days.
Analysts’ Opinion of CRDF
Many brokerage firms have already submitted their reports for CRDF stocks, with Craig Hallum repeating the rating for CRDF by listing it as a “Buy.” The predicted price for CRDF in the upcoming period, according to Craig Hallum is $8 based on the research report published on September 06, 2024 of the previous year 2024.
Robert W. Baird gave a rating of “Outperform” to CRDF, setting the target price at $19 in the report published on December 08th of the previous year.
CRDF Trading at 3.55% from the 50-Day Moving Average
After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.87% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRDF starting from Levine James E., who purchase 2,752 shares at the price of $5.42 back on Dec 17 ’24. After this action, Levine James E. now owns 65,316 shares of Cardiff Oncology Inc, valued at $14,905 using the latest closing price.
Levine James E., the Chief Financial Officer of Cardiff Oncology Inc, purchase 2,400 shares at $5.00 during a trade that took place back on Dec 18 ’24, which means that Levine James E. is holding 67,716 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for CRDF
Current profitability levels for the company are sitting at:
- -108.77 for the present operating margin
- 0.58 for the gross margin
The net margin for Cardiff Oncology Inc stands at -102.0. The total capital return value is set at -0.73. Equity return is now at value -74.15, with -61.51 for asset returns.
Based on Cardiff Oncology Inc (CRDF), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.52.
Currently, EBITDA for the company is -48.25 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 399.4. The receivables turnover for the company is 1.18for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.22.
Conclusion
To put it simply, Cardiff Oncology Inc (CRDF) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
